Literature DB >> 511351

Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 3: Pharmacokinetic characterization of sulphadiazine and sulphamethoxazole given with trimethoprim.

B Ortengren, L Magni, T Bergan.   

Abstract

Plasma levels and renal excretion of sulphonamide and trimethoprim following oral administration of co-trimazine (140 mg sulphadiazine + 90 mg trimethoprim) and co-trimoxazole (800 mg sulphamethoxazole + 180 mg trimethoprim) were monitored in healthy volunteers after a single dose and in the steady state after 12-hourly dosage. The plasma levels of free, non-protein bound components after co-trimazine were approximately half those after co-trimoxazole and thus correlated with the doses given. Urine recovery of trimethoprim was better after co-trimazine (70%) than after co-trimoxazole (58%). Sixty-six percent of the sulphadiazine was recovered as unchanged, active sulphonamide in the urine compared with only 13% of the sulphamethoxazole. Consequently, the sulphonamide levels of sulphadiazine were 2.5 times those of sulphamethoxazole. With respect to plasma half-life after the first dose, sulphadiazine with 8.0 hours was closer to trimethoprim with a half-life of 8.8 hours after cotrimazine and 9.6 hours after co-trimoxazole than to the half-life of sulphamethoxazole which was 7.7 hours. The distribution volume of sulphadiazine was closer to that of trimethoprim than was that of sulphamethoxazole. On the basis of these characteristics, it has been concluded that sulphadiazine is more suitable for a fixed combination tablet with trimethoprim than sulphamethoxazole, particularly for the treatment of urinary tract infections. Some renal tubular reabsorption occurs with both unchanged sulphonamides but is more pronounced with sulphamethoxazole. The solubilities of the sulphonamides and their acetylated metabolites at acid urinary pH indicate that therapy with co-trimazine is at least as safe as with co-trimoxazole. With the former drug, the result of scrutiny for crystals after dosage until the steady state was negative, whereas crystals of acetylated sulphamethoxazole were detected and verified chemically in two of eight subjects.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 511351     DOI: 10.1007/bf01639016

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  20 in total

1.  Pharmacokinetic studies with trimethoprim and different doses of sulfadiazine in healthy human subjects.

Authors:  P Männistö; J Tuomisto; N E Saris; T Lehtinen
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

2.  Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function.

Authors:  J Rieder; D E Schwartz; M Fernex; T Bergan; E K Brodwall; A Blumberg; P Cottier; W Scheitlin
Journal:  Antibiot Chemother (1971)       Date:  1974

3.  [Comparative bacteriological investigations with the combination trimethoprim/sulfamethoxazole in vitro and in vivo].

Authors:  E Böhni
Journal:  Chemotherapy       Date:  1969       Impact factor: 2.544

4.  Kidney transport in man of sulfamethoxazole and trimethoprim.

Authors:  T Bergan; E K Brodwall
Journal:  Chemotherapy       Date:  1972       Impact factor: 2.544

5.  Investigation of sulfonamide crystalluria in man.

Authors:  O S Alfthan; K Liewendahl
Journal:  Scand J Urol Nephrol       Date:  1972

Review 6.  Progress in sulfonamide research.

Authors:  T Struller
Journal:  Prog Drug Res       Date:  1968

7.  Influence of sulfonamide antagonists on the synergism of sulfamethoxazole-trimethoprim in Escherichia coli.

Authors:  R Then
Journal:  Zentralbl Bakteriol Orig A       Date:  1973-10

8.  Quantitative determination of the bacteriostatically active fraction of sulfonamides and the sum of their inactive metabolites in the body fluids.

Authors:  J Rieder
Journal:  Chemotherapy       Date:  1972       Impact factor: 2.544

9.  Single-blind comparative trial of trimethoprim-sulphamethoxazole and ampicillin in the treatment of exacerbations of chronic bronchitis.

Authors:  D T Hughes
Journal:  Br Med J       Date:  1969-11-22
View more
  6 in total

1.  Trimethoprim/sulphonamide: concluding remarks.

Authors:  W Marget
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 2.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of co-trimazine.

Authors:  T Bergan; B Ortengren; D Westerlund
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

Review 4.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

5.  Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function.

Authors:  T Bergan; E K Brodwall; H Vik-Mo; U Anstad
Journal:  Infection       Date:  1979       Impact factor: 3.553

6.  A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions.

Authors:  Denise Türk; Nina Hanke; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2020-11-10       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.